Results 151 to 160 of about 19,019 (189)

Effects of Integrase Inhibitor-Based ART on the NLRP3 Inflammasome Among ART-Naïve People With HIV. [PDF]

Open Forum Infect Dis, 2020
Toribio M, Burdo TH, Fulda ES, Cetlin M, Chu SM, Feldpausch MN, Robbins GK, Neilan TG, Melbourne K, Grinspoon SK, Zanni MV.   +10 more
europepmc   +1 more source

Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes

, 2011
Kendra E. Hightower, Ruolan Wang, Felix Deanda, Brian A. Johns, Kurt Weaver, Yingnian Shen, Ginger H. Tomberlin, H. Luke Carter, Timothy M Broderick, Sigethy Scott, Takahiro Seki, Masanori Kobayashi, Mark Underwood   +12 more
openalex   +1 more source

HIV-1 Integrase Inhibitor-Inspired Antibacterials Targeting Isoprenoid Biosynthesis

, 2012
Yonghui Zhang, Fu-Yang Lin, Kai Li, Wei Zhu, Yi-Liang Liu, Rong Cao, Ran Pang, Eunhae Lee, Jordan C. Axelson, Mary E. Hensler, Ke Wang, Katie J. Molohon, Yang Wang, Douglas A. Mitchell, Victor Nizet, Eric Oldfield   +15 more
openalex   +2 more sources

Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection

, 2009
Christine Katlama, Robert L. Murphy
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Integrase Strand Transfer Inhibitor Resistance in Integrase Strand Transfer Inhibitor-Naive Persons

AIDS Research and Human Retroviruses, 2021
There has been no systematic review of the prevalence of transmitted integrase strand transfer inhibitor (INSTI) resistance. We systematically searched the English-language PubMed database and GenBank to identify studies published since 2010 reporting 50 or more INSTI-naive HIV-1-infected adults undergoing integrase genotyping.
Soo-Yon Rhee, Alexander J Bailey, Robert W. Shafer   +2 more
openaire   +3 more sources

Will Integrase Inhibitors be Used as Microbicides?

Current HIV Research, 2012
Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections including HIV-1. Despite more than two decades of HIV-1 research, there is still no efficacious HIV-1 vaccine, and the scientific community appears ...
CUZZUCOLI CRUCITTI, GIULIANA, Maurizio Botta, DI SANTO, Roberto   +2 more
openaire   +4 more sources